The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Analysis of therapy attrition and changes in outcomes over time for patients (pts) with advanced urothelial cancer (aUC) treated at an academic center.
 
Kevin R Reyes
No Relationships to Disclose
 
Tanya Jindal
No Relationships to Disclose
 
Prianka Deshmukh
No Relationships to Disclose
 
Xiaolin Zhu
Employment - Exelixis (I)
 
Chien-Kuang Cornelia Ding
No Relationships to Disclose
 
Anthony C. Wong
No Relationships to Disclose
 
Carissa E Chu
No Relationships to Disclose
 
Sima P. Porten
Honoraria - American Urologic Association; Exact Sciences; Pacific Edge
Consulting or Advisory Role - AstraZeneca; Oncuria; Photocure; Stryker
Research Funding - Photocure (Inst)
 
Jonathan Chou
Consulting or Advisory Role - Exai Bio
Research Funding - Amgen (Inst)
 
Terence W. Friedlander
Leadership - Med BioGene
Honoraria - Astellas Pharma; Astellas Scientific and Medical Affairs Inc; AstraZeneca/MedImmune; EMD Serono
Consulting or Advisory Role - AADi; Astellas Pharma; Basilea; Dava Oncology; EMD Serono; Foundation Medicine; Merck; Seagen; Taiho Oncology
Research Funding - Bristol-Myers Squibb (Inst); Neon Therapeutics (Inst); Roche/Genentech (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca/MedImmune; Genentech/Roche; Jounce Therapeutics
 
Vadim S Koshkin
Consulting or Advisory Role - Clovis Oncology; Gerson Lehrman Group; Guidepoint Global; Janssen; Pfizer/EMD Serono; Seattle Genetics/Astellas
Research Funding - Clovis Oncology; Endocyte (Inst); Gilead Sciences (Inst); Gilead Sciences (Inst); Lilly (Inst); Merck (Inst); Nektar (Inst); Seagen (Inst); Taiho Oncology (Inst)